The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
 
Yuichiro Tsukada
No Relationships to Disclose
 
Tamotsu Sagawa
No Relationships to Disclose
 
Gopalakrishnan Srinivasan
No Relationships to Disclose
 
Ayala Hubert
No Relationships to Disclose
 
Ofer Purim
No Relationships to Disclose
 
Valeriya Semenisty
No Relationships to Disclose
 
Nangi Lo
No Relationships to Disclose
 
Giuseppe Mondello
No Relationships to Disclose
 
Antonio Cubillo Gracian
No Relationships to Disclose
 
Tara Marti
Employment - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
Travel, Accommodations, Expenses - Exact Sciences; Flatiron Health
 
Somasundaram Subramaniam
Employment - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
 
Melanie R. Palomares
Employment - Exact Sciences
Leadership - Cancer Prevention Movement
Stock and Other Ownership Interests - Exact Sciences; LabCorp
Travel, Accommodations, Expenses - Exact Sciences
 
Frederick Baehner
Employment - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
 
Floris A de Jong
Employment - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
 
David James Kerr
Employment - Celleron Therapeutics
Leadership - Oxford cancer biomarkers
Stock and Other Ownership Interests - Celleron Therapeutics; Oxford cancer biomarkers
Consulting or Advisory Role - Burjeel Holdings; Geno Bio; Indivumed; Medscape
Speakers' Bureau - Novartis
Patents, Royalties, Other Intellectual Property - patents pending on two biomarker tests developed for Oxford Cancer Biomarkers
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)